Objective: To assess the feasibility of retroperitoneal laparoscopic nephrectomy combined with bench surgery and autotransplantation in treating complex renal tumor. Patients and Methods: Six patients with complex renal tumor were seen in our institution between 2010 and 2014. Three patients with bilateral renal cell carcinoma underwent retroperitoneal laparoscopic nephrectomy on both sides. Extracorporeal tumorectomy and renal reconstruction were performed on the side of the smaller tumor and then kidney autotransplantation was performed. The other 3 patients with tumor involving the solitary kidney underwent laparoscopic nephrectomy combined with bench surgery and autotransplantation. Result: The total time of the operation was 287 ± 25 min; warm ischemia time 3.1 ± 0.7 min; cold ischemia time 47 ± 8.1 min; and kidney autotransplantation required time 86 ± 8.6 min. Estimated blood loss was 232 ± 45.8 ml. Serum creatinine levels were 179 ± 44.7 µmol/l upon hospital discharge. Two patients received temporary hemodialysis. No patient needed further hemodialysis during follow-up. One patient died of multiple metastases 18 months after surgery. The other 5 patients survived without recurrence or metastasis during follow-up. Conclusions: Retroperitoneal laparoscopic radical nephrectomy combined with bench surgery and autotransplantation is a feasible choice for patients with complex renal cell carcinoma in bilateral kidneys and tumor involving the solitary kidney.

Keywords:
Retroperitoneal laparoscope, Bench surgery, Autotransplantation, Bilateral renal cell carcinoma, Tumor in solitary kidney
1.
Chow WH, Dong LM, Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245-257.
2.
Ljungberg B, Campbell SC, Choi HY, et al: The epidemiology of renal cell carcinoma. Eur Urol 2011;60:615-621.
3.
Eggener SE, Rubenstein JN, Smith ND, et al: Renal tumors in young adults. J Urol 2004;171:106-110.
4.
Ghoneim TP, Sjoberg DD, Lowrance W, et al: Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics. World J Urol 2015;33:2023-2029.
5.
Novick AC: Laparoscopic and partial nephrectomy. Clin Cancer Res 2004;10(18 pt 2):6322S-6327S.
6.
Ansari J, Doherty A, McCafferty I, et al: Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin Genitourin Cancer 2009;7:E39-E41.
7.
Siemer S, Uder M, Zell A, et al: Bilateral kidney tumor. Therapy management and histopathological results with long-term follow-up of 66 patients. Urologe A 2001;40:114-120.
8.
Wiklund F, Tretli S, Choueiri TK, et al: Risk of bilateral renal cell cancer. J Clin Oncol 2009;27:3737-3741.
9.
Kito H, Suzuki H, Igarashi T, et al: Distinct patterns of chromosomal losses in clinically synchronous and asynchronous bilateral renal cell carcinoma. J Urol 2002;168:2637-2640.
10.
Klatte T, Wunderlich H, Patard JJ, et al: Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int 2007;100:21-25.
11.
Ansari MS, Gupta NP, Kumar P: Von Hippel-Lindau disease with bilateral multiple renal cell carcinoma managed by right radical nephrectomy and left repeat partial nephrectomy. Int Urol Nephrol 2003;35:471-473.
12.
Blute ML, Itano NB, Cheville JC, et al: The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol 2003;169:1276-1281.
13.
Bratslavsky G, Linehan WM: Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat Rev Urol 2010;7:267-275.
14.
Tsili AC, Argyropoulou MI: Advances of multidetector computed tomography in the characterization and staging of renal cell carcinoma. World J Radiol 2015;7:110-127.
15.
Capitanio U, Terrone C, Antonelli A, et al: Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. Eur Urol 2015;67:683-689.
16.
Becker F, Siemer S, Tzavaras A, et al: Long-term survival in bilateral renal cell carcinoma: a retrospective single-institutional analysis of 101 patients after surgical treatment. Urology 2008;72:349-353.
17.
Becker A, Ravi P, Roghmann F, et al: Laparoscopic radical nephrectomy vs laparoscopic or open partial nephrectomy for T1 renal cell carcinoma: comparison of complication rates in elderly patients during the initial phase of adoption. Urology 2014;83:1285-1291.
18.
Bayrak O, Seckiner I, Erturhan S, et al: Comparison of the complications and the cost of open and laparoscopic radical nephrectomy in renal tumors larger than 7 centimeters. Urol J 2014;11:1222-1227.
19.
Ilbeigi P, Brison D, Sadeghi-Nejad H: Synchronous bilateral laparoscopic radical nephrectomy for solid renal masses using a hybrid approach. Urol J 2008;5:192-196.
20.
Ficarra V, Galfano A, Cavalleri S: Is simple enucleation a minimal partial nephrectomy responding to the EAU guidelines' recommendations? Eur Urol 2009;55:1315-1318.
21.
Rana YP, Gupta SK, Singh DV, et al: Renal autotransplantation as savior in hybrid surgery for aortic aneurysm repair. Urol Int 2012;89:480-482.
22.
Wszolek MF, Kenney PA, Lee Y, et al: Comparison of hilar clamping and non-hilar clamping partial nephrectomy for tumours involving a solitary kidney. BJU Int 2011;107:1886-1892.
23.
Karakiewicz PI, Suardi N, Jeldres C, et al: Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845-848.
24.
Kroon BK, de Bruijn R, Prevoo W, et al: Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology 2013;81:111-115.
25.
Karam JA, Devine CE, Urbauer DL, et al: Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol 2014;66:874-880.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.